

1112_OA_Skrining - Ety - Suyata.docx

by e.yuristo@gmail.com 1

Submission date: 10-Jul-2025 07:18PM (UTC+0530)

Submission ID: 2712860857

File name: 1112_OA_Skrining_-_Ety_-_Suyata.docx (69.61K)

Word count: 4083

Character count: 25823

ORIGINAL ARTICLE

The Role of Lipopolysaccharide-Binding Protein in Hepatitis B-Related Cirrhosis: Is There a Link to Portal Hypertension?

Ety Febrianti^{1,2}, Suyata³, Legiran⁴, Imam Suprianto³, Vidi Orba Busro³, Muhamad Ayus Astoni³, Anjab Akmal Sya'roni³

10

¹Fellow in Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya /Mohammad Hoesin General Hospital, Palembang

²Department of Internal Medicine, Faculty of Medicine, Universitas Bengkulu/Mohammad Yunus Regional Hospital, Bengkulu

³Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya/Mohammad Hoesin General Hospital, Palembang

⁴Department of Anatomy, Faculty of Medicine, Universitas Sriwijaya

Corresponding author:

Suyata, Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Sriwijaya University/Mohammad Hoesin General Hospital, Palembang, email: suyata@fk.unsri.ac.id

ABSTRACT

13

Background: Bacterial translocation plays a crucial role in the pathogenesis of systemic inflammation in cirrhosis, especially in cases related to chronic Hepatitis B infection. Lipopolysaccharide-binding protein (LBP) is a key acute-phase reactant indicating exposure to endotoxins, yet its relationship with portal hypertension remains poorly defined. This study aimed to explore the correlation between serum LBP levels and spleen stiffness as a non-invasive marker of portal hypertension in patients with Hepatitis B-related cirrhosis.

Methods: A cross-sectional study was conducted on 50 patients with Hepatitis B-related cirrhosis at Dr. Mohammad Hoesin Hospital, Palembang, between September and December 2024. Serum LBP levels were measured, and spleen stiffness was assessed using transient elastography. Laboratory parameters, clinical data, and virologic profiles were analyzed. Correlation tests were performed using Pearson's or Spearman's method as appropriate.

Results: The mean LBP level was 20.49 ± 7.34 $\mu\text{g/mL}$, and the mean spleen stiffness was 71.69 ± 17.74 kPa. A negative but non-significant correlation was observed between serum LBP and spleen stiffness ($r = -0.263$, $p = 0.065$). LBP showed significant negative correlations with bilirubin (total, direct, and indirect) and transaminase levels (AST and ALT), but not with platelet count, HBV DNA, or coagulation profiles.

Conclusion: In patients with Hepatitis B-related cirrhosis, serum LBP may reflect systemic inflammatory activity rather than portal pressure severity. Further studies are needed to determine its prognostic utility in cirrhotic complications.

Keywords: Hepatitis B, cirrhosis, LBP, portal hypertension, spleen stiffness, bacterial translocation

Commented [u1]: Mohon menambahkan abstract dalam bahasa Indonesia dengan maksimal 250 kata.

ABSTRAK

Latar belakang: Translokasi bakteri merupakan mekanisme penting dalam patogenesis inflamasi sistemik pada sirosis, khususnya pada kasus yang disebabkan oleh infeksi Hepatitis B kronik. *Lipopolysaccharide-binding protein* (LBP) merupakan protein fase akut yang berperan sebagai penanda paparan endotoksin. Namun, hubungan antara kadar LBP serum dan derajat hipertensi portal masih belum jelas. Penelitian ini bertujuan untuk mengevaluasi korelasi antara kadar LBP serum dan kekakuan limpa sebagai penanda non-invasif hipertensi portal pada pasien sirosis akibat Hepatitis B.

Metode: Penelitian potong lintang ini melibatkan 50 pasien dengan sirosis akibat Hepatitis B yang dirawat di RSUP Dr. Mohammad Hoesin Palembang pada periode September hingga Desember 2024. Kadar LBP serum diukur menggunakan metode imunologis, dan kekakuan limpa dinilai dengan transient elastography. Data laboratorium, klinis, dan virologis dianalisis. Uji korelasi dilakukan menggunakan metode Pearson atau Spearman sesuai dengan distribusi data.

Hasil: Rerata kadar LBP serum sebesar $20,49 \pm 7,34$ $\mu\text{g/mL}$ dan rerata kekakuan limpa sebesar $71,69 \pm 17,74$ kPa. Terdapat korelasi negatif yang tidak signifikan antara kadar LBP dan kekakuan limpa ($r = -0,263$; $p = 0,065$). Kadar LBP menunjukkan korelasi negatif yang signifikan dengan kadar bilirubin (total, langsung, dan tidak langsung) serta enzim transaminase (AST dan ALT), namun tidak berhubungan secara signifikan dengan jumlah trombosit, kadar DNA HBV, atau profil koagulasi.

Kesimpulan: Pada pasien sirosis akibat Hepatitis B, kadar LBP serum lebih mencerminkan aktivitas inflamasi sistemik dibandingkan dengan derajat hipertensi portal. Diperlukan penelitian lebih lanjut untuk menilai potensi nilai prognostik LBP terhadap komplikasi sirosis.

Kata kunci: Hepatitis B, sirosis, LBP, hipertensi portal, kekakuan limpa, translokasi bakteri.

INTRODUCTION

Hepatitis B virus (HBV) infection remains a major global health concern, contributing significantly to the burden of chronic liver disease and cirrhosis. According to the World Health Organization (WHO), over 296 million individuals live with chronic HBV infection worldwide, with nearly 820,000 deaths annually attributed to its complications, including cirrhosis and hepatocellular carcinoma.¹ In Indonesia, HBV prevalence is among the highest in Southeast Asia, with estimates ranging from 7% to 10% in the general population.² Chronic HBV accounts for a substantial proportion of cirrhosis cases in Indonesia, placing a heavy burden on the healthcare system in terms of both mortality and financial cost.^{3,4} Hospitalizations due to decompensated cirrhosis and its complications require prolonged care, advanced diagnostics, and repeated interventions, collectively contributing to rising national healthcare expenditures.^{5,6}

Portal hypertension (PH) is a key and life-threatening complication of cirrhosis, often dictating clinical prognosis and driving the development of variceal bleeding, ascites, and hepatic encephalopathy.⁷ The pathogenesis of PH involves increased resistance to portal

blood flow due to intrahepatic architectural distortion and vascular remodeling, as well as splanchnic vasodilation that elevates portal inflow.⁸ Clinically significant portal hypertension (CSPH), defined as a hepatic venous pressure gradient (HVPG) ≥ 10 mmHg, is associated with a marked increase in the risk of variceal hemorrhage and death.⁹ However, HVPG measurement is invasive, expensive, and not widely available in routine clinical practice,¹⁰ especially in resource-limited settings like Indonesia. Consequently, spleen stiffness measurement (SSM) via elastography has gained attention as a non-invasive, reproducible alternative.⁶ Guidelines from the European Association for the Study of the Liver (EASL), American Association for the Study of Liver Diseases (AASLD), and Indonesian Association for the Study of the Liver (Ina-ASL) have acknowledged SSM as a useful surrogate marker for assessing PH in hepatitis B related-cirrhotic patients.^{11–13}

Recent advances in understanding the gut-liver axis have highlighted the role of bacterial translocation and endotoxemia in cirrhosis progression and complications.¹⁴ The impaired intestinal barrier in cirrhosis allows for microbial components such as lipopolysaccharide (LPS) to enter the portal circulation, triggering systemic immune activation.¹² Lipopolysaccharide-binding protein (LBP) is a liver-derived acute-phase protein that binds to LPS and facilitates its recognition by immune cells via the CD14/TLR4 complex.¹⁵ Elevated serum LBP levels have been proposed as a biomarker of bacterial translocation and systemic inflammation in patients with chronic liver disease.¹⁶ Due to its hepatic origin and responsiveness to endotoxemia, LBP may also reflect the functional integrity of hepatocytes and the extent of immune dysregulation in cirrhosis.

Several studies have reported elevated LBP levels in cirrhotic patients, often linked to systemic inflammation and poor outcomes, but their relationship with portal hypertension—a major predictor of mortality and complications in advanced liver disease—remains unclear. Agiasotelli et al found that elevated serum LBP predicted short-term mortality even in cirrhotic patients without overt infection.¹⁷ Albillos et al showed that cirrhotic patients with ascites and high LBP levels had marked immune and hemodynamic disturbances, though their portal pressure remained unaffected by antibiotic therapy.¹⁸ Gioia et al demonstrated in patients with portal hypertension due to porto-sinusoidal vascular disorder (PSVD) that elevated LPS and zonulin were associated with endothelial dysfunction and platelet activation, reinforcing the role of gut-derived endotoxins in portal microvascular pathology.¹⁹ In experimental models, Chuang et al revealed that LPS triggered exaggerated renal vasoconstriction in portal vein-ligated rats, suggesting that bacterial products may

exacerbate systemic vascular dysfunction in portal hypertension.²⁰ However, few studies have evaluated whether serum LBP levels correlate with non-invasive indicators of portal hypertension, such as spleen stiffness, particularly in Hepatitis B-related cirrhosis. This study aims to investigate the relationship between serum LBP and spleen stiffness to assess the potential role of LBP as a surrogate biomarker for portal hypertension in HBV-related cirrhosis.

METHODS

Study Design

This study employed a cross-sectional observational design conducted at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia, between September and December 2024. The objective was to assess the correlation between serum lipopolysaccharide-binding protein (LBP) levels and spleen stiffness as a non-invasive surrogate for portal hypertension in patients with hepatitis B-related cirrhosis.

Ethical Considerations

The research protocol was reviewed and approved by the Health Research Ethics Committee of Dr. Mohammad Hoesin General Hospital, Palembang No DP.04.03/D.XVIII.06.08/ETIKRSMH/12/2024. Prior to participation, all subjects received detailed information regarding the study objectives, procedures, and potential risks, and gave written informed consent. This study was conducted in accordance with the ethical standards of the Declaration of Helsinki.

Participants and Eligibility Criteria

Subjects were enrolled consecutively from inpatient and outpatient services in the Department of Internal Medicine, Division of Gastroenterology and Hepatology. Eligible participants were adults (≥ 18 years old) with clinically and/or radiologically diagnosed cirrhosis secondary to chronic hepatitis B virus (HBV) infection. Exclusion criteria included concurrent hepatocellular carcinoma, other causes of liver disease, active infection, recent use of antibiotics or probiotics, autoimmune disorders, or history of splenectomy.

Data Collection

Clinical data were collected through structured interviews and medical records. Laboratory evaluations included complete blood count, liver function tests, coagulation profile, and quantitative HBV DNA. Serum LBP levels were measured using enzyme-linked immunosorbent assay (ELISA). Spleen stiffness was assessed using Vibration-Controlled

Transient Elastography (VCTE) performed by trained sonographers, with measurements taken under fasting conditions and standardized technique.

Statistical Analysis

Statistical analysis was performed using IBM SPSS Statistics version 26.0. Data normality was assessed with the Kolmogorov-Smirnov test. Normally distributed data were presented as mean ± standard deviation, while non-normally distributed variables were expressed as median (minimum–maximum). Correlation analysis between LBP and clinical or elastographic variables was conducted using Pearson's or Spearman's test as appropriate. A p-value < 0.05 was considered statistically significant. To further assess the relationship between serum LBP levels and spleen stiffness as a dependent variable, simple linear regression analysis was performed. Variables with p < 0.25 in bivariate correlation were considered for inclusion in the regression model. A p-value < 0.05 was considered statistically significant, with 95% confidence intervals reported where applicable.

RESULTS

Data in Table 1 describes the general characteristics, laboratory findings, and imaging results of the 50 subjects with hepatitis B-related cirrhosis. The mean age was 55.34 ± 8.46 years, with a predominance of male subjects (68%). The average body mass index was 22.83 ± 3.87 kg/m². Clinical features included ascites (50%), esophageal varices (46%), and splenomegaly (80%), while none presented with hepatic encephalopathy. Based on the Child-Pugh classification, 48% of patients were classified as class A, 46% as class B, and 6% as class C.

Table 1. General Characteristics, Laboratory Findings, and Imaging Results of Study Participants

Characteristics	Participants (n=50)
Age (years)	55.34±8.46
Sex	
Male (n, %)	34 (68%)
Female (n, %)	16 (32%)
Body Mass Index (kg/m²)	22.83±3.87
Clinical Manifestations	
Ascites (n, %)	25 (50%)
Esophageal Varices (n, %)	23 (46%)
Hepatic Encephalopathy (n, %)	0
Splenomegaly (n, %)	40 (80%)
Child Pugh Turcotte Score (CP)	7 (5-11)
CP Class A (n, %)	24 (48%)

CP Class B (n, %)	23 (46%)
CP Class C (n, %)	3 (6%)
Laboratory Findings	
Hemoglobin (g/dL)	11.32±2.12
Leukocyte (/mm ³)	5716.20±2159.07
Platelets (/mm ³)	98260±35183
Absolute Eosinophil Count (/mm ³)	150.47±98.08
Absolute Neutrophil Count (/mm ³)	3059.80 (989.4-8177)
Absolute Lymphocyte Count (/mm ³)	1462.81±630.50
Absolute Monocyte Count (/mm ³)	459 (211.80-1515.60)
Total Bilirubin (mg/dL)	1.25 (0.50-10.80)
Conjugated Bilirubin (mg/dL)	0.60 (0.20-7.70)
11: conjugated Bilirubin (mg/dL)	0.60 (0.20-3.60)
AST (IU/L)	41.50 (17-98)
ALT (IU/L)	39.88±17.98
Albumin (g/dL)	3.21±0.75
Urea (mg/dL)	25 (8-100)
Creatinine (mg/dL)	0.90 (0.50-3.10)
INR	1.27 (1.07-2.12)
Immunoserology and Virology	
HBsAg positivity (n, %)	5 (10%)
HBV DNA (IU/mL)	481800 (0-1.46x10 ⁷)
Lipopolysaccharide binding protein (ng/ml)	20.49±7.34
Imaging	
Spleen Stiffness (kPa)	71.69±17.74
Liver Stiffness 9 (kPa)	24.65 (12.5-75)

CP: Child-Pugh; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; INR: International normalized ratio; HBV DNA: Hepatitis B virus Deoxyribonucleic acid

Mean hemoglobin was 11.32 ± 2.12 g/dL, with a mean platelet count of 98,260 ± 35,183/mm³. Median total bilirubin was 1.25 mg/dL, while median SGOT was 41.50 IU/L and mean SGPT was 39.88 ± 17.98 IU/L. Mean serum albumin was 3.21 ± 0.75 g/dL. The mean serum LBP level was 20.49 ± 7.34 µg/mL. The mean spleen stiffness measured by elastography was 71.69 ± 17.74 kPa, and median liver stiffness was 24.65 kPa (range 12.5–75).

Table 2. Correlation between LBP and Spleen Stiffness

		Spleen Stiffness (kPa)	
Variable		r	p
Lipopolysaccharide protein (µg/ml)	binding	-0.263	0.065

Commented [u2]: Mohon integrasikan table 2 ke dalam kalimat "as shown in table 2....."

As shown in Table 2, bivariate analysis revealed a negative correlation between serum LBP and spleen stiffness ($r = -0.263$), although this result did not reach statistical significance ($p = 0.065$). However, multivariate linear regression analysis (Table 3) demonstrated that serum LBP was a significant predictor of spleen stiffness ($B = -0.66$; 95% CI: -1.22 to -0.09 ; $p = 0.024$). Other significant predictors included hemoglobin ($p = 0.001$), INR ($p = 0.008$), and the presence of splenomegaly ($p = 0.001$). Female gender showed a borderline association ($p = 0.061$). The final regression model yielded an adjusted R^2 of 0.378.

Table 3. Linear Regression Analysis of Predictors of Spleen Stiffness

Variable	Bivariate		Multivariate		
	r	p	B	IK95%	p
LBP (ng/ml)	-0.26	0.065 ¹	-0.66	-1.22 sd -0.09	0.024
Age (years)	-0.08	0.559 ¹			
Body Mass Index (kg/m ²)	-0.05	0.705¹			
Skor CP	0.18	0.210²			
Hemoglobin (g/dL)	-0.29	0.044¹	-3.48	-5.51 sd -1.46	0.001
Leukocyte (/mm ³)	-0.02	0.868 ¹			
Platelets (/mm ³)	-0.01	0.973 ¹			
Absolute Eosinophil Count (/mm ³)	-0.19	0.174 ¹			
Absolute Neutrophil Count (/mm ³)	0.01	0.952 ²			
Absolute Lymphocyte Count (/mm ³)	-0.22	0.119 ¹			
Absolute Monocyte Count (/mm ³)	0.09	0.542 ²			
Total Bilirubin (mg/dL)	0.02	0.878 ²			
Conjugated Bilirubin (mg/dL)	0.04	0.803 ²			
Unconjugated Bilirubin (mg/dL)	0.03	0.827 ²			
AST (IU/L)	0.06	0.677 ²			
ALT (IU/L)	-0.09	0.537 ¹			
Albumin (g/dL)	-0.27	0.055 ¹			
Urea (mg/dL)	0.08	0.560 ²			
Creatinine (mg/dL)	0.02	0.911 ²			
INR	0.29	0.038²	23.97	6.49 sd 41.45	0.008
HBV DNA (IU/mL)	-0.11	0.428 ²			
Liver Stiffness (kPa)	0.13	0.363 ²			
Female			-8.75	-17.90 sd 0.40	0.061
Clinical Splenomegaly		9	16.97	6.98 sd 27.03	0.001

LBP: Lipopolysaccharide-binding protein; CP: Child-Pugh; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; INR: International normalized ratio; HBV DNA: Hepatitis B virus Deoxyribonucleic acid

DISCUSSIONS

This study investigated the relationship between serum lipopolysaccharide-binding protein (LBP) and spleen stiffness (SS) in patients with hepatitis B-related cirrhosis and identified a significant inverse association between these two parameters in multivariate analysis. While bivariate testing did not yield statistical significance, adjustment for key covariates revealed that higher LBP levels were associated with lower SS values. This is a notable finding, as spleen stiffness is an established non-invasive surrogate for portal pressure, and LBP is increasingly recognized as a marker of microbial translocation and systemic immune activation. These results suggest that LBP, despite being a pro-inflammatory marker, does not uniformly increase in tandem with portal hypertension severity and may instead reflect earlier or dynamic immune states in cirrhosis progression.

The negative correlation between LBP and spleen stiffness observed in multivariate models may appear counterintuitive but can be explained by the complex

immunopathological landscape of chronic hepatitis B cirrhosis. In early or compensated stages, LBP may rise in response to increased gut-derived endotoxin exposure, reflecting heightened immune surveillance and preserved hepatic synthetic function.^{21,22} As the disease advances and liver function deteriorates, LBP synthesis may decline, while portal hypertension and spleen stiffness increase due to long-standing vascular resistance and fibrotic remodeling.²³ This decoupling of LBP from SS in late-stage disease may account for the lack of correlation in unadjusted analysis. Additionally, spleen stiffness, although correlated with portal pressure, can be influenced by splenic congestion, fibrosis, or inflammation—factors not directly aligned with transient changes in endotoxin-driven immune responses.²⁴ The non-significant association between LBP and liver stiffness in this cohort further supports the idea that LBP is more reflective of immune activation than fibrotic or hemodynamic burden alone, as seen in studies by Simbrunner et al and Albillos et al.^{18,25}

Previous studies have demonstrated varying relationships between LBP and markers of portal hypertension, though consistent correlations remain elusive. For example, Albillos et al identified elevated LBP levels in ascitic cirrhotic patients, which were associated with systemic inflammatory markers (such as IL-6 and TNF- α), immune activation (e.g., SCD14), and reduced vascular resistance, suggesting hemodynamic alterations secondary to bacterial translocation.¹⁸ However, their study notably reported that LBP levels did not correlate with portal pressure itself, as measured by HVPG, thereby suggesting that LBP may reflect immune dysregulation rather than direct mechanical pressure. Similarly, Simbrunner et al found that elevated LBP was part of an early immune activation profile in compensated cirrhosis, but again, this increase was not necessarily linked to portal hypertensive severity.²⁵ These findings support the current study's results, where LBP was not significantly correlated with spleen stiffness in univariate analysis, but showed a significant negative association after multivariate adjustment, indicating the presence of confounding variables such as hemoglobin and INR. One plausible interpretation is that LBP elevation occurs in early disease stages, when gut-derived endotoxin exposure is high and hepatic synthesis is still preserved, while spleen stiffness — as a proxy for portal hypertension — tends to rise with later vascular remodeling and congestion.^{25,26} As such, LBP and SS may represent distinct but intersecting biological processes along the cirrhosis continuum: the former an indicator of immune activation, the latter a result of long-standing portal resistance. This

temporal dissociation could explain the seemingly paradoxical inverse association observed in adjusted models.

The pathophysiological relevance of LBP in cirrhosis centers on its role as a mediator of the innate immune response to circulating lipopolysaccharides (LPS), which translocate from the gut due to compromised intestinal barriers^{27,28} LBP facilitates the binding of LPS to CD14 and TLR4 receptors on monocytes and macrophages, triggering the release of inflammatory cytokines such as TNF- α and IL-6.²⁹ These mediators contribute to systemic vasodilation, endothelial dysfunction, and further decompensation in cirrhosis, but their immediate impact on portal pressure or splenic remodeling may be modest or delayed. Thus, while LBP is a sensitive marker of microbial translocation, it may not linearly reflect the mechanical changes assessed by spleen stiffness.

Interestingly, the relationship between LBP and biochemical indices such as aminotransferases and albumin offers further insight into the state of hepatocellular function. Lower LBP levels in patients with higher Child-Pugh scores and reduced hemoglobin may reflect hepatic synthetic failure, as LBP is produced predominantly by hepatocytes.³⁰ This could explain why, in some cases, patients with severe portal hypertension and high SS values exhibited low LBP concentrations. The dissociation between inflammatory markers and fibrotic burden is not unique to LBP, as seen in other inflammatory liver conditions where immune activation precedes structural damage.

From a clinical perspective, these findings emphasize the importance of using integrated biomarkers to assess cirrhotic progression. While spleen stiffness remains a promising tool for non-invasive estimation of portal pressure, its interpretation may benefit from concurrent evaluation of systemic immune markers like LBP. In settings where hepatic venous pressure gradient (HVPG) is unavailable, this combination could offer a pragmatic approach to identifying patients at risk of complications related to portal hypertension. Moreover, the inclusion of LBP in predictive algorithms may enhance the stratification of patients in both research and practice, especially in chronic HBV-endemic regions.

The strength of this study lies in its focused cohort of hepatitis B-related cirrhotic patients and the use of objective spleen stiffness measurement via elastography. This narrow confounding from etiologic heterogeneity and improves internal validity. However, several limitations merit consideration. The cross-sectional design limits temporal interpretation of causality. The modest sample size, though powered for preliminary associations, may underdetect subtle interactions. Additionally, the exclusion of other bacterial translocation

markers, such as sCD14 or endotoxin levels, restricts the ability to contextualize LBP within the broader immune landscape. Future studies should incorporate these markers and explore longitudinal trajectories of LBP in relation to spleen stiffness and portal hemodynamics. Despite these limitations, our findings contribute to the evolving understanding of the gut-liver axis in cirrhosis and suggest that serum LBP, when interpreted within a multivariable framework, may offer insight into the inflammatory dynamics associated with portal hypertension. This opens avenues for developing non-invasive, integrative models to monitor cirrhotic patients, particularly in hepatitis B-endemic areas.

CONCLUSIONS

Serum LBP levels were inversely associated with spleen stiffness in patients with hepatitis B-related cirrhosis, suggesting a potential but complex link between bacterial translocation and portal hypertension. Future studies should incorporate these markers and explore longitudinal trajectories of LBP in relation to spleen stiffness and portal hemodynamics.

REFERENCES

1. Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. *Nat Rev Gastroenterol Hepatol*. 2023 Aug;20(8):524–37.
2. Lusida MI, Juniastuti, Yano Y. Current hepatitis B virus infection situation in Indonesia and its genetic diversity. *World J Gastroenterol*. 2016 Aug 28;22(32):7264–74.
3. H Muljono D. Epidemiology of Hepatitis B and C in Republic of Indonesia. *Euroasian J Hepatogastroenterol*. 2017;7(1):55–9.
4. Yano Y, Utsumi T, Lusida MI, Hayashi Y. Hepatitis B virus infection in Indonesia. *World J Gastroenterol*. 2015 Oct 14;21(38):10714–20.
5. Lim SG, Amarapurkar DN, Chan HLY, Crawford DH, Gane EJ, Han KH, et al. Reimbursement policies in the Asia-Pacific for chronic hepatitis B. *Hepatol Int*. 2015 Jan 1;9(1):43–51.
6. Jasirwan COM. Adakah Perubahan Kesintasan Karsinoma Sel Hati di Indonesia? *JPDJ*. 2020 Oct 2;7(3):133.
7. Premkumar M, Anand AC. Overview of Complications in Cirrhosis. *Journal of Clinical and Experimental Hepatology*. 2022 Jul 1;12(4):1150–74.
8. Jagdish RK, Roy A, Kumar K, Premkumar M, Sharma M, Rao PN, et al. Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-

on-chronic liver failure. *Front Med* [Internet]. 2023 Jun 15 [cited 2025 Jun 6];10. Available from: <https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1060073/full>

9. Kulkarni AV, Rabiee A, Mohanty A. Management of Portal Hypertension. *Journal of Clinical and Experimental Hepatology*. 2022 Jul 1;12(4):1184–99.
10. Garcia-Pagán JC, Schepis F, Gaba RC, Zanetto A, Perez-Campuzano V, Haskal ZJ, et al. HVPg as a Gold Standard: Accuracy Is Essential. In: de Franchis R, editor. *Portal Hypertension VII*. Cham: Springer International Publishing; 2022. p. 45–60.
11. Franchis R de, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII – Renewing consensus in portal hypertension. *Journal of Hepatology*. 2022 Apr 1;76(4):959–74.
12. Kaplan DE, Ripoll C, Thiele M, Fortune BE, Simonetto DA, Garcia-Tsao G, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. *Hepatology*. 2024 May;79(5):1180.
13. Kumiawan J, Sulaiman AS, Lesmana CRA, Bayupurnama P, Bestari MB, Akil F, et al. National Consensus on Portal Hypertension Management in Indonesia. *Acta Med Indones*. 2022 Apr;54(2):324–46.
14. Juanola O, Francés R, Caparrós E. Exploring the Relationship between Liver Disease, Bacterial Translocation, and Dysbiosis: Unveiling the Gut-Liver Axis. *Visceral Medicine*. 2024 Jan 23;40(1):12–9.
15. Schumann RR, Zweigner J. A novel acute-phase marker: lipopolysaccharide binding protein (LBP). *Clin Chem Lab Med*. 1999 Mar;37(3):271–4.
16. Alexopoulou A, Agiasotelli D, Vasilieva LE, Dourakis SP. Bacterial translocation markers in liver cirrhosis. *Ann Gastroenterol*. 2017;30(5):486–97.
17. Agiasotelli D, Alexopoulou A, Vasilieva L, Hadziyannis E, Goukos D, Daikos GL, et al. High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis. *Liver International*. 2017;37(4):576–82.
18. Albillos A, de la Hera A, González M, Moya JL, Calleja JL, Monserrat J, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. *Hepatology*. 2003;37(1):208–17.
19. Gioia S, Carnevale R, Tavano D, Overi D, Ridola L, Nardelli S, et al. Association between gut-derived endotoxins and porto-sinusoidal vascular disorder with portal hypertension. *Alimentary Pharmacology & Therapeutics*. 2023;58(11–12):1205–16.
20. Chuang CL, Huang HC, Chang CC, Lee FY, Wu JC, Lee JY, et al. Lipopolysaccharide enhanced renal vascular response to endothelin-1 through ETA overexpression in portal hypertensive rats. *Journal of Gastroenterology and Hepatology*. 2015;30(1):199–207.

21. Hasa E, Hartmann P, Schnabl B. Liver cirrhosis and immune dysfunction. *Int Immunol*. 2022 Sep 6;34(9):455–66.
22. Kumar R, Kumar S, Prakash SS. Compensated liver cirrhosis: Natural course and disease-modifying strategies. *World J Methodol*. 2023 Sep 20;13(4):179–93.
23. Engelmann C, Clària J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. *Journal of Hepatology*. 2021 Jul 1;75:S49–66.
24. Du L, Deng H, Wu X, Liu F, Yin T, Zheng J. Relationship Between Spleen Pathologic Changes and Spleen Stiffness in Portal Hypertension Rat Model. *Ultrasound in Medicine & Biology*. 2024 Feb 1;50(2):216–23.
25. Simbrunner B, Caparrós E, Neuwirth T, Schwabl P, Königshofer P, Bauer D, et al. Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response. *Hepatol Int*. 2023 Aug;17(4):1045–56.
26. Rigamonti C. Spleen stiffness in portal hypertension algorithms: the next advance. *The Lancet Gastroenterology & Hepatology*. 2024 Dec 1;9(12):1067–9.
27. Schnabl B, Brenner DA. Interactions Between the Intestinal Microbiome and Liver Diseases. *Gastroenterology*. 2014 May 1;146(6):1513–24.
28. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*. 2017 Dec 14;9(6):7204–18.
29. Tuomi K, Logomarsino JV. Bacterial Lipopolysaccharide, Lipopolysaccharide-Binding Protein, and Other Inflammatory Markers in Obesity and After Bariatric Surgery. *Metabolic Syndrome and Related Disorders*. 2016 Aug;14(6):279–88.
30. Milbank E, Díaz-Trelles R, Dragano N, Latorre J, Mukthavaram R, Mayneris-Perxachs J, et al. Liver lipopolysaccharide binding protein prevents hepatic inflammation in physiological and pathological non-obesogenic conditions. *Pharmacological Research*. 2023 Jan 1;187:106562.

ORIGINALITY REPORT

13%

SIMILARITY INDEX

10%

INTERNET SOURCES

14%

PUBLICATIONS

3%

STUDENT PAPERS

PRIMARY SOURCES

1

"Posters (Abstracts 289–2348)", Hepatology, 2019

Publication

1%

2

5dok.net

Internet Source

1%

3

journals.lww.com

Internet Source

1%

4

"Abstracts", Hepatology International, 2020

Publication

1%

5

"Abstracts—APASL 2013", Hepatology International, 2013

Publication

1%

6

Shu-Hsien Lin, Chih-Yun Lin, Nien-Tzu Hsu, Yi-Hao Yen et al. "Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information", Journal of the Formosan Medical Association, 2022

Publication

1%

7

Ying Li, Xin Zeng, Lei Zhou. "Ultrasound-guided peripheral nerve radiofrequency ablation for craniofacial postherpetic neuralgia: efficacy and safety in a retrospective cohort", Journal of Clinical Neuroscience, 2025

Publication

1 %

8

www.researchgate.net

Internet Source

1 %

9

Dai, C.Y.. "Early mortality in taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors", Clinical Therapeutics, 200612

Publication

1 %

10

conference.fk.unsri.ac.id

Internet Source

1 %

11

Danai Agiasotelli, Alexandra Alexopoulou, Larisa Vasilieva, Emilia Hadziyannis et al. "High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis", Liver International, 2017

Publication

1 %

link.springer.com

12	Internet Source	1 %
13	oaji.net Internet Source	1 %
14	"Abstracts of the 27th Annual Conference of APASL, March 14–18, 2018, New Delhi, India", Hepatology International, 2018 Publication	1 %
15	"Portal Hypertension VII", Springer Science and Business Media LLC, 2022 Publication	1 %
16	rjn.com.ro Internet Source	1 %
17	www.frontiersin.org Internet Source	1 %
18	www2.kenes.com Internet Source	1 %
19	www.mdpi.com Internet Source	1 %

Exclude quotes On

Exclude matches < 1%

Exclude bibliography On